Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. de Haas SL, et al. Among authors: lewis gd. Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z. Breast Cancer Res. 2023. PMID: 36631725 Free PMC article. Clinical Trial.
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, Huang CS, Loibl S, Mamounas EP, Geyer CE, Lucas PC, Boulet T, Song C, Lewis GD, Nowicka M, de Haas S, Basik M. Denkert C, et al. Among authors: lewis gd. Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. doi: 10.1158/1078-0432.CCR-22-1989. Clin Cancer Res. 2023. PMID: 36730339 Free PMC article.
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E. Lewis GD, et al. Nat Commun. 2024 Jan 11;15(1):466. doi: 10.1038/s41467-023-44533-z. Nat Commun. 2024. PMID: 38212321 Free PMC article. Clinical Trial.
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.
Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, Pradhan RN, Wang AW, Sanchez PL, Qu Y, Breart B, Chalouni C, Dunlap D, Ziai J, Elstrott J, Zacharias N, Mao W, Rowntree RK, Sadowsky J, Lewis GD, Pillow TH, Nabet BY, Banchereau R, Tam L, Caothien R, Bacarro N, Roose-Girma M, Modrusan Z, Mariathasan S, Müller S, Turley SJ. Krishnamurty AT, et al. Among authors: lewis gd. Nature. 2022 Nov;611(7934):148-154. doi: 10.1038/s41586-022-05272-1. Epub 2022 Sep 28. Nature. 2022. PMID: 36171287 Free PMC article.
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy.
Adhikari P, Li G, Go M, Mandikian D, Rafidi H, Ng C, Anifa S, Johnson K, Bao L, Hernandez Barry H, Rowntree R, Agard N, Wu C, Chou KJ, Zhang D, Kozak KR, Pillow TH, Lewis GD, Yu SF, Boswell CA, Sadowsky JD. Adhikari P, et al. Among authors: lewis gd. J Am Chem Soc. 2024 Jul 17;146(28):19088-19100. doi: 10.1021/jacs.4c03529. Epub 2024 Jul 1. J Am Chem Soc. 2024. PMID: 38946086
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Clardy SM, Uttard A, Du B, Catcott KC, Lancaster KL, Ditty E, Sadowsky J, Zurita J, Malli N, Qin L, Bradley SP, Avocetien K, Carter T, Kim D, Nazzaro M, Xu L, Pillow TH, Zacharias NT, Lewis GD, Rowntree RK, Iyengar R, Lee DH, Damelin M, Toader D, Lowinger TB. Clardy SM, et al. Among authors: lewis gd. Mol Cancer Ther. 2024 Jan 3;23(1):84-91. doi: 10.1158/1535-7163.MCT-23-0262. Mol Cancer Ther. 2024. PMID: 37774393
Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration.
Kovacs G, Humbert M, Avian A, Lewis GD, Ulrich S, Vonk Noordegraaf A, Souza R, Galiè N, Malhotra R, Saxer S, Grünig E, Egenlauf B, Ewert R, Heine A, Tedford RJ, Houston BA, Kasperowicz K, Kurzyna M, Rosenkranz S, Herkenrath S, Barbera JA, Blanco I, Oliveira RKF, Andersen M, Savale L, Systrom D, Maron BA, Tello K, Condliffe R, Mak S, Baratto C, Hsu S, D'Alto M, McCabe C, Herve P, Olschewski H; PEX-NET (Pulmonary Haemodynamics during Exercise Network) ERS Clinical Research Collaboration. Kovacs G, et al. Among authors: lewis gd. Eur Respir J. 2024 Nov 27;64(6):2400698. doi: 10.1183/13993003.00698-2024. Print 2024 Dec. Eur Respir J. 2024. PMID: 39603672 Free PMC article.
Extended duration of ex-vivo perfusion is associated with worse survival in donation after circulatory death heart recipients: A national database analysis.
Singh R, Olverson G, Punu K, Makarem A, Chukwudi CC, Brownlee SA, Kreso A, Rabi SA, Michel E, Lewis GD, D'Alessandro DA, Osho AA. Singh R, et al. Among authors: lewis gd. J Heart Lung Transplant. 2024 Nov 20:S1053-2498(24)01961-2. doi: 10.1016/j.healun.2024.11.018. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 39577509
364 results